Bristol-Myers Squibb says it will pay a record $1.85 billion to Nektar Therapeutics, a small biotech startup, for rights to its experimental cancer drug, codenamed NKTR-214. Nektar will book 65% of global profits on the drug, should it reach the market, with Bristol getting the other 35%.
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2018/02/14/bristol-myers-to-pay-largest-licensing-fee-in-biotech-history-for-cancer-drug/
via IFTTT
No comments:
Post a Comment